CMS Data on COVID Hospitalizations Underscores Need for Urgent Action to Protect Vulnerable Americans

American Kidney Fund urges Administration to release complete, nationwide data on pandemic impact

ROCKVILLE, MD / ACCESSWIRE / June 24, 2020 / The American Kidney Fund (AKF) today expressed deep concern about preliminary new data from the Centers for Medicare & Medicaid Services (CMS) indicating that end-stage renal disease (ESRD, or kidney failure) patients and Black Americans had vastly higher rates of hospitalization for COVID-19.

“The new CMS data on COVID hospitalizations among Medicare patients is the tip of the pandemic iceberg,” said LaVarne A. Burton, AKF president and CEO. “Racial and ethnic minorities are already disproportionately affected by kidney failure, and the double-whammy impact of COVID on Black Americans and those with kidney failure requires an urgent response from the federal government.”

According to the preliminary CMS data-which covers the period from January 1 to May 16-Blacks were nearly four times more likely than whites to be hospitalized with COVID-19, and Americans eligible for Medicare because they have ESRD had the highest COVID-19 hospitalization rate.

“It is absolutely urgent that we see all the data pertaining to the experience of minority populations with COVID-19, overlaid with chronic disease data to give us a full picture that will inform appropriate action to address the disproportionate impact,” Burton said.

More than half the dialysis patients in the United States are under 65, though most of them qualify for Medicare because of their kidney failure. People of all races and ethnicities develop chronic kidney disease (CKD) at similar rates, but minorities, including Blacks and Hispanic/Latinos, are more likely to progress to kidney failure. This disparity is evident in the racial and ethnic makeup of the low-income ESRD patients who receive financial assistance from AKF, including those receiving help from AKF’s Coronavirus Emergency Fund-most of those receiving grants are people of color.

About Us

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

CONTACT:

Alice Andors
Senior Director of Communications
aandors@kidneyfund.org
11921 Rockville Pike, Suite 300, Rockville, MD 20852
Work: 240-292-7053 Mobile: 703-609-6085
KidneyFund.org

SOURCE: American Kidney Fund

View source version on accesswire.com:
https://www.accesswire.com/594986/CMS-Data-on-COVID-Hospitalizations-Underscores-Need-for-Urgent-Action-to-Protect-Vulnerable-Americans

Staff

Recent Posts

Bemax Announces Financial Results for Fiscal Fourth Quarter Ended May 31, 2024

- Revenue increase of over 600%Dallas, Georgia--(Newsfile Corp. - July 2, 2024) - Bemax Inc.…

1 hour ago

1933 Industries Reports Profit in Q3 2024 Financials

VANCOUVER, BC / ACCESSWIRE / July 2, 2024 / 1933 Industries Inc. (the "Company" or…

1 hour ago

Myriad Genetics Earns 2024 Great Place To Work® Certification™

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a…

1 hour ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid…

1 hour ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG…

1 hour ago